It has also been shown to reduce the expression of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 in chronic fatigue syndrome (CFS) patients after six-eight weeks of clinical therapy [5,6]. This evidence concerns the gene TNF and myalgic encephalomeyelitis/chronic fatigue syndrome.